Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mainstay Medical International PLC

www.mainstay-medical.com

Latest From Mainstay Medical International PLC

Trial Results Fail To Support Mainstay Medical's Neuromodulation Device

Mainstay Medical says it will move forward with a US PMA application for its ReActiv8 neuromodulation therapy for chronic back pain even though the ReActiv8 clinical trial failed to reach its primary endpoint.

Clinical Trials Neurology

Market Intel: Peripheral Nerve Stim Players Edge Out Innovative Paths

While demand for spinal cord stimulation (SCS) devices used in pain management continues to expand at double-digit rates, a small but growing number of highly innovative companies that develop stimulators to specifically target peripheral nerve pain is creating excitement among pain doctors looking for better options to treat an intractable population that's seen little success with standard therapy. With millions of people worldwide suffering from low back pain, severe headaches and migraines, neck pain and other chronic pain, the demand for safe, effective, percutaneously-placed devices remains high. In this article, we'll highlight emerging companies working on PNS devices and provide insights from pain physicians on the pros and cons of these devices.

Neurology Commercial

Mainstay Will Supplement Australian ReActiv8 Application With ReActiv8 B Data

Australia's Therapeutic Goods Administration asked for additional clinical data on Mainstay Medical's ReActiv8 neurostimulation device for chronic low-back pain, so the company will provide clinical data from the ongoing ReActiv8 B trial.

Clinical Trials Innovation

Mainstay Medical Reaches Milestone With Interim Results Of US Clinical Trial

Mainstay Medical is making steps towards the US commercialization of its neurostimulation system ReActiv8. The company announced a positive outcome from interim analysis of its US ReActiv8 B clinical trial which aims to gather data in support of an application for pre-market approval from the US FDA.

Neurology Clinical Trials
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Mainstay Medical Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Mainstay Medical International PLC
  • Senior Management
  • Peter Crosby, Pres. & CEO
    Hugh Kavanagh, CFO
    Jan Pieter Heemels, VP, Commercial Ops.
  • Contact Info
  • Mainstay Medical International PLC
    Clonmel House, Forster Way
    Swords, Dublin,
    Ireland
UsernamePublicRestriction

Register